The Johns Hopkins University report identifies systemic gaps in NCD
research, policy and practice
Offering pragmatic actions and sustainable solutions, experts cite
multisectoral cooperation as vital
Independent research project stems from IFPMA Framework for Action on
NCDs, focusing on innovation, access and affordability, prevention and
health education, and partnerships
GENEVA, Feb. 4, 2013 /CNW/ - Today the Johns Hopkins University's
Institute for Applied Economics, Global Health and the Study of
Business Enterprise released a focused set of policy briefs that
provide actionable recommendations for improving NCD policy, research
and, ultimately, care. The study was commissioned by the International
Federation of Pharmaceutical Manufacturers & Associations (IFPMA).
The four main NCD categories - cardiovascular disease, cancer, chronic
lung diseases and diabetes - kill three in five people worldwide.
Nearly 80% of NCD deaths occur in low- and middle-income countries.
As part of momentum from the 2011 United Nations High Level Meeting on
the Prevention and Control of NCDs, a working group of leading scholars produced this collection of briefs: Addressing the Gaps in Global Policy and Research for Non-Communicable
Diseases. Their findings provide decision-makers with five key areas for action:
1) strengthening supply chains, 2) accelerating regulatory convergence,
3) applying HIV/AIDS learnings to improve access to interventions, 4)
restructuring primary care, and 5) promoting multisectoral action.
"We harnessed the direction given by UN Member States in the NCD
Political Declaration as a springboard for action," said Sir George
Alleyne, former director of the Pan American Health Organization
(PAHO), and co-author of one of the briefs. "Based on this direction,
our work paves a way forward to achieve better health outcomes through
multisectoral and intersectoralcooperation."
Eduardo Pisani, IFPMA Director General, said, "The research-based
pharmaceutical industry commissioned these briefs to generate ideas
which we hope will contribute to WHO discussions and provide a path
forward where our industry is best prepared to play its part with other
The Johns Hopkins policy briefs can be accessed (http://www.ifpma.org/resources/publications.html).
Authors include: Brian White-Guay, Lisa Smith, PrashantYadav,
SoerenMattke, Margaret Kruk, Felicia Knaul, Gustavo Nigenda, Sir George
Alleyne, and SaniaNishtar. Jeffrey L.Sturchio and Louis Galambos served
IFPMA represents research-based pharmaceutical companies and
associations across the globe. The research-based pharmaceutical
industry's 1.3 million employees research, develop and provide
medicines and vaccines that improve the life of patients worldwide.
Based in Geneva, IFPMA has official relations with the United Nations
and contributes industry expertise to help the global health community
find solutions that improve global health.
SOURCE: International Federation of Pharmaceutical Manufacturers and Associations
For further information:
Peter Shelby, IFPMA, Tel +41-22-338-32-23, email@example.com